艾地苯醌联合左旋多巴治疗帕金森病患者的效果  

Effects of Idebenone combined with Levodopa in treatment of patients with Parkinson’s disease

作　　者：刘明 LIU Ming(Department of Neurology of Zhecheng County People’s Hospital,Shangqiu 476200 Henan,China)

机构地区：[1]柘城县人民医院神经内科,河南商丘476200

出　　处：《中国民康医学》2024年第7期27-29,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察艾地苯醌联合左旋多巴治疗帕金森病患者的效果。方法:选取2021年2月至2023年2月该院收治的68例帕金森病患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各34例。对照组予以左旋多巴治疗,观察组在对照组基础上联合艾地苯醌治疗,两组均持续治疗12周。比较两组临床疗效,治疗前后认知功能[蒙特利尔认知评估量表(MoCA)]评分、运动功能[统一帕金森病评定量表第Ⅲ部分(UPDRSⅢ)]评分、氧化应激指标[超氧化物歧化酶(SOD)、8-羟基脱氧鸟苷酸(8-OHDG)、丙二醛(MDA)]水平,以及不良反应发生率。结果:观察组治疗总有效率为97.06%(33/34),高于对照组的76.47%(26/34),差异有统计学意义(P<0.05);治疗后,观察组MoCA评分高于对照组,差异有统计学意义(P<0.05);治疗后,观察组UPDRSⅢ评分低于对照组,差异有统计学意义(P<0.05);治疗后,观察组MDA、8-OHDG水平均低于对照组,SOD水平高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:艾地苯醌联合左旋多巴治疗帕金森病患者可提高治疗总有效率、认知功能评分,降低运动功能评分,改善氧化应激指标水平,效果优于单纯左旋多巴治疗。Objective:To observe effects of Idebenone combined with Levodopa in treatment of patients with Parkinson’s disease.Methods:A prospective study was conducted on 68 patients with Parkinson’s disease admitted to the hospital from February 2021 to February 2023.According to the random number table method,they were divided into control group and observation group,34 cases in each group.The control group was treated with Levodopa,while the observation group was treated with Idebenone on the basis of that of the control group.Both groups were treated for 12 weeks.The clinical efficacy,the cognitive function[Montreal cognitive assessment(MoCA)]score,the motor function[unified Parkinson’s disease rating scale Part III(UPDRS III)]score,the oxidative stress indexes[superoxide dismutase(SOD),8-hydroxydeoxyguanosine(8-OHDG),malondialdehyde(MDA)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 97.06%(33/34),which was higher than that of the control group 76.47%(26/34),and the difference was statistically significant(P<0.05).After the treatment,the MoCA score of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After the treatment,the UPDRS III score of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of MDA and 8-OHDG in the observation group were lower than those in the control group,the level of SOD was higher than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Idebenone combined with Levodopa in the treatment of the Parkinson’s disease patients can improve the total effective rate of treatment,the cognitive function scores,reduce the motor function scores,and im

关 键 词：艾地苯醌 左旋多巴 帕金森病 认知功能 氧化应激 运动功能 不良反应 

分 类 号：R742.5[医药卫生—神经病学与精神病学]